A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With Multiple Sclerosis
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Biogen Idec
- 23 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Oct 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 05 Mar 2009 Additional lead trial investigators identified as reported by ClinicalTrials.gov, last updated 5-Mar-2009.